Eckert & Ziegler SE: Steady Growth and Strategic Positioning

NuWays AG has reaffirmed its "BUY" recommendation for Eckert & Ziegler SE (EUZ), setting a target price of EUR 23 over the next 12 months. Unlike single product healthcare companies, EUZ's strategy focuses on providing regulated radioisotopes across a range of nuclear medicine applications, thereby mitigating risk.

The preliminary financial results for FY25 reveal a robust performance, with Q4 sales reaching €87.9m, a 9% year-on-year increase, despite foreign exchange challenges. Adjusted EBIT surged by 41% to €27.2m, driven by higher license sales. Expectations for 2026 include a 7% increase in sales, primarily from radiopharma growth.

Noteworthy developments include new market potential in China with Telix's PSMA PET product and significant expansion prospects in therapeutic isotopes for prostate cancer and neuroendocrine tumors, suggesting a promising trajectory for EUZ.